Phase 2 N=118 Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay
Cesarean Section
Primary: Discharge on Postoperative Day #2 — 5; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab — 2 Participants
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=16 Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
Glioblastoma Multiforme · Glioblastoma - Category
Primary: Overall Survival (OS) — 11.73 months
Phase 2 N=28 Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Acromegaly
Primary: Determination of the Maximum Tolerated Dose (MTD) by Number of Subjects With DLTs. — 0; 0; 0 participants
Phase 2 N=68 A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide
Major Depressive Disorder
Primary: Change From Baseline to Day 1: 4-Hour Post-dose in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Double-blind Phase) — -9.1; -13.4 Units on a scale
Phase 2 N=39 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
Hepatitis C Virus Infection
Primary: For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF — 12682.5; 8210.3; 11688.9; 10202.4 h*ng/mL
Phase 2 N=4 Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial
Cocaine Use Disorders
Primary: Cocaine Use — 3; 1; 1; 0 Participants
Phase 2 N=479 Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
Autistic Disorder · Autism · Asperger's Disorder
Primary: Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases) — 69.0; 67.5; 66.7 Percentage of…
Phase 2 N=76 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Myelodysplastic Syndrome · Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia
Primary: Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT) — 22.1; 21.9; 14.3 percentage…
Phase 2 N=11 DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Leukemia · Myelodysplastic Syndromes · Blastic Plasmacytoid Dendritic Cell Neoplasm
Primary: Overall Response Rate (CR+PR+SD): Percentage of Participants Experiencing Response — 81.8 percentage of participants
Phase 2 N=22 Plerixafor for Stem Cell Mobilization in Normal Donors
Blood And Marrow Transplantation
Primary: Summary of Most Common Toxicity: Donor Safety in Mobilizing Peripheral Blood Progenitor Cells (PBPC) — 1; 2; 2; 2 adverse events
Phase 2 N=52 Study to Demonstrate Cognitive Enhancing Effects of BF2.649
Schizophrenia
Primary: Changes in Delayed Recall From Baseline to 12 Weeks — 40.2; 43.4 t-score
Phase 2 N=104 Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
Phase 2 N=3 Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Liver Cancer · Liver Neoplasm · Hepatocellular Carcinoma
Primary: Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure — 0 Participants